STOCK TITAN
  1. Home
  2. News
  3. CRSP

CRISPR Therapeutics AG - CRSP STOCK NEWS

Welcome to our dedicated page for CRISPR Therapeutics news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics stock.

CRISPR Therapeutics AG (symbol: CRSP) is a pioneering gene editing company dedicated to the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary technology allows for precise, directed changes to genomic DNA, enabling the treatment of genetically defined diseases.

The company's portfolio spans a broad range of therapeutic programs, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. One of its notable achievements is the development and approval of Casgevy, a therapeutic targeting sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals.

To bolster its research and development, CRISPR Therapeutics has forged strategic partnerships with renowned companies such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. These collaborations aim to accelerate and expand the company's efforts in bringing novel therapies to market.

Headquartered in Zug, Switzerland, CRISPR Therapeutics operates through its wholly-owned U.S. subsidiary, with R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California, and London, United Kingdom.

The company's ongoing projects include advancing gene editing programs in immuno-oncology and developing stem cell-derived therapies for the treatment of Type 1 diabetes. With its innovative approach and strategic collaborations, CRISPR Therapeutics is at the forefront of the gene editing revolution, poised to make significant impacts in the field of medicine.

For more information, please visit www.crisprtx.com.

News

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
CRISPR Therapeutics achieves significant milestones in gene-based medicines with multiple clinical trials ongoing and a strengthened balance sheet through a $280 million offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
earnings
-
News

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at Citi 2024 Virtual Oncology Leadership Summit, offering a live webcast and replay option for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
conferences
-
News

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Rhea-AI Summary
CRISPR Therapeutics (CRSP) secures $280 million investment to advance clinical trials and gene writing programs, strengthening balance sheet with over $2.1 billion in pro forma cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
offering
News

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Rhea-AI Summary
CRISPR Therapeutics receives conditional marketing authorization from the European Commission for CASGEVY, a gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. Over 8,000 eligible patients in the EU may benefit from this approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
News

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Rhea-AI Summary
The U.S. FDA has approved CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older. CRISPR Therapeutics, the biopharmaceutical company behind the treatment, is working with Vertex Pharmaceuticals to establish a network of treatment centers throughout the U.S. to offer CASGEVY to eligible patients. This approval reflects the power and versatility of the CRISPR platform to bring potentially curative treatment options to patients suffering from devastating diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
none
-
News

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Rhea-AI Summary
CRISPR Therapeutics (CRSP) highlights 2024 outlook, strategic priorities, and recent achievements, including the first-ever approval of a CRISPR-based gene-editing therapy and entering the clinic with in vivo therapies. The company plans to expand its pipeline, drive clinical trials, and innovate on its platform with next-generation gene editing and delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
News

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
conferences
-
News

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) announced the FDA approval of CASGEVY™, a CRISPR-based gene-editing therapy, for the treatment of sickle cell disease in patients 12 years and older. This marks the first-ever approval of a CRISPR-based gene-editing therapy in the U.S. and offers a one-time treatment option for approximately 16,000 eligible patients with severe sickle cell disease. The therapy has the potential to eliminate severe vaso-occlusive crises and hospitalizations caused by the disease, providing a functional cure for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
fda approval
-
News

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) provided an update on its immuno-oncology pipeline, focusing on next-generation CAR T product candidates CTX112™ targeting CD19 and CTX131™ targeting CD70. Preliminary data from ongoing clinical trials suggest that these candidates may improve upon the clinical profile of first-generation candidates CTX110 and CTX130, with increased CAR T cell expansion and functional persistence. The Company is transitioning patients treated with CTX110 and CTX130 to long-term follow-up and plans to expand trials of CTX112 into autoimmune disease and CTX131 into hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
News

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced the first regulatory authorization of a CRISPR-based gene-editing therapy in the world. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy is indicated for eligible patients 12 years of age and older. CASGEVY has been authorized for the treatment of patients with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. The safety profile of patients treated with CASGEVY in clinical trials is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none

FAQ

What is the current stock price of CRISPR Therapeutics (CRSP)?

The current stock price of CRISPR Therapeutics (CRSP) is $46.85 as of October 11, 2024.

What is the market cap of CRISPR Therapeutics (CRSP)?

The market cap of CRISPR Therapeutics (CRSP) is approximately 3.9B.

What is CRISPR Therapeutics AG?

CRISPR Therapeutics AG is a gene editing company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform.

What does the CRISPR/Cas9 platform do?

CRISPR/Cas9 is a revolutionary gene editing technology that enables precise, directed changes to genomic DNA, allowing for the treatment of genetically defined diseases.

Where is CRISPR Therapeutics headquartered?

CRISPR Therapeutics is headquartered in Zug, Switzerland, with additional offices in the U.S. and the UK.

What is Casgevy?

Casgevy is a therapeutic developed by CRISPR Therapeutics in collaboration with Vertex Pharmaceuticals, targeting sickle cell disease and transfusion-dependent beta-thalassemia.

What types of diseases is CRISPR Therapeutics targeting?

CRISPR Therapeutics is targeting a range of diseases including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

Who are CRISPR Therapeutics' key partners?

CRISPR Therapeutics has established strategic collaborations with companies like Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc.

What are some of CRISPR Therapeutics' current projects?

Current projects include advancing gene editing programs for immuno-oncology and developing stem cell-derived therapies for Type 1 diabetes.

Where are CRISPR Therapeutics' R&D operations based?

The company's R&D operations are based in Cambridge, Massachusetts.

How has CRISPR Therapeutics impacted the field of medicine?

CRISPR Therapeutics is at the forefront of the gene editing revolution, developing innovative therapies for serious diseases and collaborating with leading companies.

Where can I find more information about CRISPR Therapeutics?

More information about CRISPR Therapeutics can be found on their website at www.crisprtx.com.

Stock CRSP logo
CRISPR Therapeutics AG

Nasdaq:CRSP

CRSP Rankings

#1433 Ranked by Market Cap
N/A Ranked by Dividends

CRSP Stock Data

3.87B
85.17M
1.74%
71.27%
19.32%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ZUG